FDA approves new antibiotic for staph, other infections
Editor's Note
The US Food and Drug administration approved Zevtera for treating Staphylococcus aureus bacteremia (SAB) bloodstream infections, which are often acquired in healthcare settings.
In the April 3 announcement, the agency notes the new antibiotic Zevtera (ceftobiprole medocaril sodium for injection) is effective for SAB-infected patients with right-sided infective endocarditis as well as two other conditions: adults with acute bacterial skin and skin structure infections (ABSSSI) as well as community-acquired bacterial pneumonia (CABP) in adult patients and children older than three months.
The full announcement contains further details on efficacy in treating the three conditions, side effects and warnings, and the approval to Basilea Pharmaceutica International Ltd.
Free Daily News
- Medical device coating could reduce blood clot risks
- FDA pilot program aims to expedite high-risk medical device recall communication
- Surgeons implant first medically suspended heart pump in US
- Study: COVID-19's impact on oncological surgery offers lessons for future crises
- Study links pandemic stress to persistent increases in nursing-sensitive quality indicators
- Save the date for the 2025 OR Business Management Conference
- Study: Education, exercise improve knee OA with or without prior surgery
- Study: Early surgery outperforms endoscopy for long-term pancreatitis
- Study: Blood thinner, NSAID combination raises bleeding risk
- Hospital financial report predicts stability, high cybersecurity costs for 2025